MiroBio, a spin-off from the University of Oxford, is a clinical-stage private biotechnology company focused on developing therapeutic agents and checkpoint agonist antibodies to restore immune balance in autoimmune patients.
MiroBio is tracked in the Tech.eu funding database. Based in Oxford, UK; active in Healthtech. Acquired by Gilead Sciences in 2022. Data as of 23 Aug 2026.
